Literature DB >> 832907

Lipid A antiserum-mediated protection against lipopolysaccharide- and lipid A-induced fever and skin necrosis.

E T Rietschel, C Galanos.   

Abstract

The antiendotoxic activity of lipid A antiserum was studied in rabbits, using lipid A (lipopolysaccharide)-induced fever and skin necrosis as test systems. It was found that lipid A antiserum had no significant antipyretic effect when it was incubated with lipid A or injected intravenously before lipid A challenge. However, in animals that were pretreated (day 0) with a single dose of lipid A (lipopolysaccharide), a significant protective effect of passively transferred antiserum (day 1) to lipid A (lipopolysaccharide fever) (day 2) was observed. Also, the lipid A (lipopolysaccharide)-induced local shwartzman reaction could be prevented by lipid A antiserum. In the fever system, the degree of protection depended on the preparative and the challenge doses as well as on the amount of antiserum transferred. The fever protection mediated by lipid A antiserum seemed to be lipid A (lipopolysaccharide) specific with regard to both the preparative and the challenge injections. Lipid A specificity of the protective factor present in the antiserum was indicated by the fauggest that the factor might be identical with lipid A-specific immunoglobulin. The significance of the preparative injection is not understood at the present time. Iti is concluded, however, that in the fever protection system described, besides specific humoral factors, other factors, perhaps cellular, are involved.

Entities:  

Mesh:

Substances:

Year:  1977        PMID: 832907      PMCID: PMC421326          DOI: 10.1128/iai.15.1.34-49.1977

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  19 in total

1.  MECHANISMS OF ENDOTOXIN TOLERANCE. 3. THE REFRACTORY STATE DURING CONTINUOUS INTRAVENOUS INFUSIONS OF ENDOTOXIN.

Authors:  S E GREISMAN; W E WOODWARD
Journal:  J Exp Med       Date:  1965-06-01       Impact factor: 14.307

2.  Treatment and prevention of intravascular coagulation with antiserum to endotoxin.

Authors:  A I Braude; H Douglas; C E Davis
Journal:  J Infect Dis       Date:  1973-07       Impact factor: 5.226

3.  Mechanisms of endotoxin tolerance. 8. Specificity of serum transfer.

Authors:  S E Greisman; E J Young; B DuBuy
Journal:  J Immunol       Date:  1973-11       Impact factor: 5.422

4.  Passive immunization against the local Shwartzman reaction.

Authors:  A I Braude; H Douglas
Journal:  J Immunol       Date:  1972-02       Impact factor: 5.422

5.  Role of antibodies in reactions to gram-negative bacterial endotoxins.

Authors:  Y B Kim; D W Watson
Journal:  Ann N Y Acad Sci       Date:  1966-06-30       Impact factor: 5.691

6.  Pyrogenicity and immunogenicity of lipid A complexed with bovine serum albumin or human serum albumin.

Authors:  E T Rietschel; Y B Kim; D W Watson; C Galanos; O Lüderitz; O Westphal
Journal:  Infect Immun       Date:  1973-08       Impact factor: 3.441

7.  A new method for the extraction of R lipopolysaccharides.

Authors:  C Galanos; O Lüderitz; O Westphal
Journal:  Eur J Biochem       Date:  1969-06

8.  Chemical structure of lipopolysaccharides and endotoxin immunity.

Authors:  E T Rietschel; O Lüderitz
Journal:  Z Immunitatsforsch Exp Klin Immunol       Date:  1975-07

9.  MODIFICATION OF HOST RESPONSES TO BACTERIAL ENDOTOXINS. I. SPECIFICITY OF PYROGENIC TOLERANCE AND THE ROLE OF HYPERSENSITIVITY IN PYROGENICITY, LETHALITY, AND SKIN REACTIVITY.

Authors:  D W WATSON; Y B KIM
Journal:  J Exp Med       Date:  1963-09-01       Impact factor: 14.307

10.  The mitogenic effect of lipopolysaccharide on bone marrow-derived mouse lymphocytes. Lipid A as the mitogenic part of the molecule.

Authors:  J Andersson; F Melchers; C Galanos; O Lüderitz
Journal:  J Exp Med       Date:  1973-04-01       Impact factor: 14.307

View more
  20 in total

1.  Salmonella synthesizing 1-dephosphorylated [corrected] lipopolysaccharide exhibits low endotoxic activity while retaining its immunogenicity.

Authors:  Qingke Kong; David A Six; Kenneth L Roland; Qing Liu; Lillian Gu; C Michael Reynolds; Xiaoyuan Wang; Christian R H Raetz; Roy Curtiss
Journal:  J Immunol       Date:  2011-06-01       Impact factor: 5.422

2.  Characterization of the epitope specificity of murine monoclonal antibodies directed against lipid A.

Authors:  H M Kuhn; L Brade; B J Appelmelk; S Kusumoto; E T Rietschel; H Brade
Journal:  Infect Immun       Date:  1992-06       Impact factor: 3.441

Review 3.  Immunoprophylaxis and immunotherapy of gram-negative sepsis and shock with antibodies to core glycolipids and lipid A of bacterial lipopolysaccharides.

Authors:  I G Mitov; D G Terziiski
Journal:  Infection       Date:  1991 Nov-Dec       Impact factor: 3.553

Review 4.  New technologies in developing recombinant attenuated Salmonella vaccine vectors.

Authors:  Shifeng Wang; Qingke Kong; Roy Curtiss
Journal:  Microb Pathog       Date:  2012-11-08       Impact factor: 3.738

Review 5.  Immunotherapeutic advances in the treatment of gram-negative bacterial sepsis.

Authors:  D L Dunn
Journal:  World J Surg       Date:  1987-04       Impact factor: 3.352

6.  A direct enzyme-linked immunosorbent assay (ELISA) for antibodies to enterobacterial Re core glycolipid and lipid A. Results in healthy subjects and in patients infected by gram-negative bacteria.

Authors:  M Nys; P Damas; F Damas; L Joassin; J Demonty
Journal:  Med Microbiol Immunol       Date:  1987       Impact factor: 3.402

7.  Inhibition of lipopolysaccharide mitogenicity with characterized anti-lipid A monoclonal antibodies.

Authors:  R Girard; R Chaby
Journal:  Immunology       Date:  1985-11       Impact factor: 7.397

8.  On the pyrogenic action of intravenous lipid A in rabbits.

Authors:  E Kenedi; H Laburn; D Mitchell; F P Ross
Journal:  J Physiol       Date:  1982-07       Impact factor: 5.182

9.  Biological activities of synthetic lipid A analogs: pyrogenicity, lethal toxicity, anticomplement activity, and induction of gelation of Limulus amoebocyte lysate.

Authors:  K Tanamoto; U Zähringer; G R McKenzie; C Galanos; E T Rietschel; O Lüderitz; S Kusumoto; T Shiba
Journal:  Infect Immun       Date:  1984-05       Impact factor: 3.441

10.  A broadly cross-protective monoclonal antibody binding to Escherichia coli and Salmonella lipopolysaccharides.

Authors:  F E Di Padova; H Brade; G R Barclay; I R Poxton; E Liehl; E Schuetze; H P Kocher; G Ramsay; M H Schreier; D B McClelland
Journal:  Infect Immun       Date:  1993-09       Impact factor: 3.441

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.